glp 1 drugs and vision problems Danny D. | 👁️ Important safety update from the *BMJ*: Emerging evidence regulatory reviews are prompting new warnings about a potential link Emerging Concerns: GLP-1 Modulators and

Microdosing for weight loss strategies were not

Key Takeaways of the GLP-1 Receptor Agonist Market Based on drug class, the liraglutide segment is projected to dominate, holding a share of 26.5% in 2026

Unhealthy diets and sedentary lifestyles are pivotal predisposing factors contributing to the growing global burden of obesity, T2DM, and metabolic dysfunction-associated fatty liver disease (MAFLD)

Data Charting Relevant information from each included study was extracted using a data charting form that captured the following fields: author(s), year of publication, country of origin, whether the combination was an add-on or simultaneously used, study population characteristics relevant to the outcomes, and sample size, study design, intervention or exposition type and details of these, comparator, outcomes and their specifics, adverse effects reports, and key findings related to the scoping review questions

One feature making this trial particularly interesting is the choice of medicine